Genzyme at buy rating from Jefferies

Jefferies & Co., Inc. analyst Adam Walsh rated Genzyme Corp. at a buy ahead of third-quarter results. Walsh is estimating earnings per share of $0.72 compared to Street consensus of $0.71. Strong product sales growth, including Synvisc and Fabryzyme, in the second quarter should continue, strengthened by the Myozyme launch. Shares of the Cambridge, Mass.-based biotechnology company were down 38 cents, or 0.56%, at $67.98. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.